Hepatitis B immune globulin - OMRIX Biopharmaceuticals

Drug Profile

Hepatitis B immune globulin - OMRIX Biopharmaceuticals

Alternative Names: HBIG - OMRIX Biopharmaceuticals; Human-specific anti-hepatitis B immunoglobulin (anti HBsAg) - OMRIX Biopharmaceuticals; Omri-Hep-B; Omri-Hep-B IV

Latest Information Update: 13 Jul 2010

Price : $50

At a glance

  • Originator OMRIX Biopharmaceuticals
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top